UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Bevacizumab for newly diagnosed ovarian cancers: Best candidates among high-risk disease patients (icon-7)

Colomban, O; Tod, M; Peron, J; Perren, TJ; Leary, A; Cook, AD; Sajous, C; ... You, B; + view all (2021) Bevacizumab for newly diagnosed ovarian cancers: Best candidates among high-risk disease patients (icon-7). JNCI Cancer Spectrum , 4 (3) , Article pkaa026. 10.1093/JNCICS/PKAA026. Green open access

[thumbnail of pkaa026.pdf]
Preview
Text
pkaa026.pdf - Published Version

Download (847kB) | Preview

Abstract

Bevacizumab is approved as a maintenance treatment in first-line setting in advanced-stage III-IV ovarian cancers, because GOG-0218 and ICON-7 phase III trials demonstrated progression-free survival benefits. However, only the subgroup of patients with high-risk diseases (stage IV, and incompletely resected stage III) derived an overall survival (OS) gain in the ICON-7 trial (4.8 months). The modeled CA-125 elimination rate constant K (KELIM) parameter, based on the longitudinal CA- 125 kinetics during the first 100 days of chemotherapy, is a potential indicator of the tumor primary chemo-sensitivity. In the ICON-7 trial dataset, the OS of patients within the low- and high-risk disease groups was assessed according to treatment arms and KELIM. Among the patients with high-risk diseases, those with favorable standardized KELIM of at least 1.0 (n=214, 46.7%) had no survival benefit from bevacizumab, whereas those with unfavorable KELIM less than 1.0 (n=244, 53.2%) derived the highest OS benefit (absolute difference = 9.1 months, 2-sided log-rank P=.10; Cox hazard ratio = 0.78, 95% confidence interval = 0.58 to 1.04, 2-sided P=.09).

Type: Article
Title: Bevacizumab for newly diagnosed ovarian cancers: Best candidates among high-risk disease patients (icon-7)
Open access status: An open access version is available from UCL Discovery
DOI: 10.1093/JNCICS/PKAA026
Publisher version: http://dx.doi.org/10.1093/JNCICS/PKAA026
Language: English
Additional information: © The Author(s) 2020. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: chemotherapy regimen, ca-125 antigen, phase 3 clinical trials, kinetics, neoplasms, ovarian cancer, bevacizumab, elimination rate constant, progression-free survival, datasets
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL
URI: https://discovery.ucl.ac.uk/id/eprint/10123745
Downloads since deposit
31Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item